For decades, surgery dominated the clinical response to skin cancer. Today, a profound shift is underway — and health system leaders who fail to recognize it risk falling behind a rapidly evolving oncology landscape.

Immunotherapy has moved from experimental option to front-line standard, rewriting protocols and restructuring care pathways across hospitals and cancer centers worldwide. Understanding how immunotherapy is reshaping skin cancer treatment isn’t just a clinical imperative — it’s a strategic one for every leader overseeing an oncology program in 2026.

From Scalpel to Systemic: The Clinical Pivot in Skin Cancer Treatment

The shift from surgical-first to systemic therapy is the defining clinical story of the past five years — and health systems are still catching up to its implications.

Checkpoint inhibitors — particularly PD-1 and CTLA-4 blockers — have fundamentally altered the trajectory of skin cancer treatment for advanced and metastatic cases. Agents like cemiplimab (Libtayo) and pembrolizumab (Keytruda) now anchor treatment regimens that once relied almost exclusively on excision and radiation. In October 2025, the FDA approved Libtayo as the first immunotherapy specifically indicated to reduce recurrence risk in high-risk cutaneous squamous cell carcinoma patients following surgery and radiation — a milestone that signals a new era in adjuvant oncology.

What Health System Leaders Must Prioritize in Skin Cancer Treatment Programs

Clinical breakthroughs only generate value when health systems build the infrastructure and governance to deliver them reliably at scale.

The rapid expansion of immunotherapy in skin cancer treatment creates both an opportunity and an obligation for oncology program directors. Health systems now need dedicated multidisciplinary tumor boards that include dermatologists, medical oncologists, and radiation specialists working in concert. Biomarker testing — particularly PD-L1 expression and tumor mutational burden — must become standard workup, not an afterthought.

Leaders must also address immune-related adverse events (irAEs). Combination regimens involving both PD-1 and CTLA-4 inhibitors yield superior survival outcomes, but they carry a higher burden of systemic immune toxicity. Building irAE management pathways — including endocrinology, gastroenterology, and rheumatology co-management protocols — is now a programmatic necessity, not a luxury.

The Next Frontier: TIL Therapy, mRNA Vaccines, and Personalized Skin Cancer Treatment

Beyond checkpoint inhibitors, a second wave of innovation is emerging — and health system leaders need to understand it now to plan for implementation tomorrow.

Experts forecast that 2026 will bring continued advancements in cellular therapies — including tumor-infiltrating lymphocyte (TIL) therapies and next-generation T-cell approaches — that are being engineered for greater persistence and potency in the tumor microenvironment. For skin cancer, TIL therapy represents a particularly promising frontier given the immune-responsive nature of melanoma and squamous cell tumors.

Simultaneously, personalized mRNA cancer vaccines — such as the V940 (mRNA-4157) candidate being evaluated alongside pembrolizumab in resectable cutaneous squamous cell carcinoma — signal a near future where skin cancer treatment is tailored at the genomic level. Health systems that invest now in precision oncology infrastructure — genomic sequencing pipelines, biobank capabilities, and AI-assisted pathology — will be positioned to adopt these therapies as they receive regulatory approval.

Equity, Access, and the Strategic Imperative in Skin Cancer Treatment Delivery

Immunotherapy’s clinical promise means little if health systems fail to close the access gap — and healthcare leaders bear direct responsibility for that outcome.

The rapid pace of innovation in skin cancer treatment has created a widening divide between academic medical centers and community hospitals. Patients in rural or underserved settings often lack access to PD-1 inhibitor protocols, specialist tumor boards, and biomarker testing infrastructure. For health system executives, this isn’t just an equity issue — it’s a population health metric, a value-based care performance indicator, and an increasingly visible regulatory concern.

Health systems should actively explore teleoncology partnerships, community oncologist training programs, and formulary standardization across network sites to ensure immunotherapy reaches every patient who qualifies. The FDA’s 2025 approval landscape, including expanded indications for Libtayo, signals that immunotherapy options in high-risk skin cancer settings are growing — making equitable access planning an urgent boardroom conversation.

ALSO READ: Ovarian Cancer Treatment Options in the U.S.: What’s Standard in 2026

Lead the Shift or Follow It

The immunotherapy revolution in skin cancer treatment is not a future trend — it is the present reality of oncology. Health system leaders who act now to align their programs with combination immunotherapy protocols, invest in precision oncology infrastructure, and build equitable access pathways will define the standard of care in their markets. Those who wait will find themselves retrofitting programs that peers built intentionally. The science has spoken clearly. The strategic question now belongs to leadership.